프레스

프레스 커버리지

순위에 있는 회사에 대한 헤드라인, 공공 뉴스 소스에서 수집. 원본 기사로 링크하고 재발행하지 않습니다 — 감정 태그는 키워드 기반입니다. 편집자의 판단이 아닙니다.

커버리지를 표시하는 Bristol-Myers Squibb Company (BMS)

31 헤드라인 · 1,721 회사 커버

1–31 중 31

2026-10-17
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
Bristol-Myers Squibb Company (BMS)· 247wallst.com
2026-10-17
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers Squibb Company (BMS)· fool.com
2026-10-17
When Amgen's Forecast And Chart Say The Same Thing, Pay Attention
Bristol-Myers Squibb Company (BMS)· trefis.com
2026-10-17
Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?
Bristol-Myers Squibb Company (BMS)· trefis.com
2026-10-17
Is Amgen Stock Increasing Your Market Risk?
Bristol-Myers Squibb Company (BMS)· trefis.com
2026-10-16
Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol-Myers Squibb Company (BMS)· 247wallst.com
2026-10-16
Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-16
How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-15
How Has Merck's Story Changed?
Bristol-Myers Squibb Company (BMS)· trefis.com
2026-10-15
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-15
Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-15
A $600,000 Dividend Portfolio Has a $52,900 Tax Problem. Here’s the Roth Solution
Bristol-Myers Squibb Company (BMS)· 247wallst.com
2026-10-15
How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-15
Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-15
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
Bristol-Myers Squibb Company (BMS)· pharmavoice.com
2026-10-14
What Could Send Regeneron Stock Higher?
Bristol-Myers Squibb Company (BMS)· trefis.com
2026-10-14
These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?
Bristol-Myers Squibb Company (BMS)· 247wallst.com
2026-10-14
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-14
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-10-14
CIBC to launch additional U.S. Canadian Depositary Receipts
Bristol-Myers Squibb Company (BMS)· finance.yahoo.com
2026-05-21
BMS-Claude Agreement Signals AI Integration Shift in Pharma - Pharmaceutical Commerce
Bristol-Myers Squibb Company (BMS)· www.pharmaceuticalcommerce.com
2026-04-01
Piramal Pharma Completes Acquisition of Kenalog Injectable Product from Bristol-Myers Squibb - scanx.trade
Bristol-Myers Squibb Company (BMS)· scanx.trade
2026-01-15
Immunai Collaborates with Bristol Myers Squibb Company to Advance Clinical Development Through Immune System Intelligence - WebWire
Bristol-Myers Squibb Company (BMS)· www.webwire.com
2026-01-15
Immunai, BMS Join Forces to Advance Clinical Development - Contract Pharma
Bristol-Myers Squibb Company (BMS)· www.contractpharma.com
2025-12-12
BMS Investing $400 Million in Dublin Sterile Drug Expansion - Industrial Info Resources
Bristol-Myers Squibb Company (BMS)· www.industrialinfo.com
2025-07-28
Stewart’s Denial of Institution on Two Amgen IPRs Highlights Possible Tension Between Drug Pricing, USPTO Priorities - IPWatchdog
Bristol-Myers Squibb Company (BMS)· ipwatchdog.com
2024-06-07
ANTITRUST—D.N.J.: Monopoly claims against Bristol-Myers Squibb, Celgene over Thalomid, Relimid drugs dismissed - VitalLaw.com
Bristol-Myers Squibb Company (BMS)· www.vitallaw.com
2022-06-07
Bristol Myers Squibb Sues Biocon For Patent Infringement Over Leukemia Drug - Law Street Media
Bristol-Myers Squibb Company (BMS)· lawstreetmedia.com
2019-07-16
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative - PR Newswire
Bristol-Myers Squibb Company (BMS)· www.prnewswire.com
2017-06-22
U.S. Supreme Court Reverses California’s Sliding Scale Approach to Specific Personal Jurisdiction - www.akingump.com
Bristol-Myers Squibb Company (BMS)· www.akingump.com
2013-03-18
WellPoint and Bristol-Myers Squibb Cut Ties to ALEC, Making 44 Corporations Out - PR Watch
Bristol-Myers Squibb Company (BMS)· www.prwatch.org